Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, the generic version of Compazine®1 Tablets, 5 mg and 10 mg, of GlaxoSmithKline, have been given final approval by the United States Food & Drug Administration (U.S. FDA). Glenmark Pharmaceuticals Ltd. (Glenmark) is an innovation-driven, international pharmaceuticals company. Glenmark Pharmaceuticals Inc., USA will market Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, in the United States.
During the twelve months ending in January 2023, sales of Compazine® Tablets, 5 mg and 10 mg were estimated by IQVIATM to have been $26.9 million*.
The current portfolio of Glenmark includes 46 ANDAs that are awaiting FDA approval and 182 medications that are currently approved for distribution in the US market. Glenmark continues to look for and investigate external development partnerships in addition to these internal filings to strengthen and hasten the expansion of its current pipeline and portfolio.
